Determination of imipenem and cilastatin sodium in Primaxin by first order derivative ultraviolet spectrophotometry.
A UV-spectrophotometric assay to measure the concentrations of the active drug components (imipenem and cilastatin) or Primaxin for routine release testing is described. The assay is based on the use of first order derivative spectrophotometry. The trough amplitudes in the first derivative spectrophotometric spectra at 243 and 318 nm were selected to determine cilastatin and imipenem, respectively. A linear relationship (R > 0.99) between the trough amplitudes and concentrations was demonstrated over the range 14-42 micrograms ml-1 for both drug components. Commercial IV formulations and laboratory prepared mixtures containing both drugs in different proportions were assayed using the developed method with good recoveries (ave. 100.6%). The method is rapid, precise, accurate and was shown to be equivalent to the more time consuming LC method; which is currently used for routine release testing. The specificity and stability indicating properties of the method will also be addressed.
Forsyth
R J
RJ
Pharmaceutical Research and Development Department, Merck Research Laboratories, West Point, PA 19486.
Ip
D P
DP
D002021:Buffers; D002853:Chromatography, Liquid; D015377:Cilastatin / Q000032:analysis; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000032:analysis*; D015378:Imipenem / Q000032:analysis; D009025:Morpholines; D013056:Spectrophotometry, Ultraviolet
D002021:Buffers; D004338:Drug Combinations; D009025:Morpholines; D015377:Cilastatin; C008550:morpholinopropane sulfonic acid; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination